Anti-Integrin αvβ6 Antibody Titer As a Predictive Biomarker of Future Treatment Escalation in Patients With Ulcerative Colitis
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Livanos A, Dunn A, Fischer J, Ungaro R, Turpin W, Lee S
. Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative Colitis. Gastroenterology. 2023; 164(4):619-629.
PMC: 10284061.
DOI: 10.1053/j.gastro.2022.12.042.
View
2.
Muramoto Y, Nihira H, Shiokawa M, Izawa K, Hiejima E, Seno H
. Anti-Integrin αvβ6 Antibody as a Diagnostic Marker for Pediatric Patients With Ulcerative Colitis. Gastroenterology. 2022; 163(4):1094-1097.e14.
DOI: 10.1053/j.gastro.2022.06.026.
View
3.
Kuwada T, Shiokawa M, Kodama Y, Ota S, Kakiuchi N, Nannya Y
. Identification of an Anti-Integrin αvβ6 Autoantibody in Patients With Ulcerative Colitis. Gastroenterology. 2021; 160(7):2383-2394.e21.
DOI: 10.1053/j.gastro.2021.02.019.
View
4.
Rydell N, Ekoff H, Hellstrom P, Moverare R
. Measurement of Serum IgG Anti-Integrin αvβ6 Autoantibodies Is a Promising Tool in the Diagnosis of Ulcerative Colitis. J Clin Med. 2022; 11(7).
PMC: 8999661.
DOI: 10.3390/jcm11071881.
View
5.
Turner D, Ricciuto A, Lewis A, DAmico F, Dhaliwal J, Griffiths A
. STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD. Gastroenterology. 2020; 160(5):1570-1583.
DOI: 10.1053/j.gastro.2020.12.031.
View